Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
McKinsey
Boehringer Ingelheim
AstraZeneca

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ABC294640

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug ABC294640?

ABC294640 is an investigational drug.

There have been 4 clinical trials for ABC294640. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, and Lymphoma, B-Cell. The leading clinical trial sponsors are RedHill Biopharma Limited, Apogee Biotechnology Corporation, and National Cancer Institute (NCI).

There are six US patents protecting this investigational drug and thirty-eight international patents.

Recent Clinical Trials for ABC294640
TitleSponsorPhase
A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular CarcinomaApogee Biotechnology CorporationPhase 2
A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular CarcinomaMedical University of South CarolinaPhase 2
A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular CarcinomaNational Cancer Institute (NCI)Phase 2

See all ABC294640 clinical trials

Clinical Trial Summary for ABC294640

Top disease conditions for ABC294640
Top clinical trial sponsors for ABC294640

See all ABC294640 clinical trials

US Patents for ABC294640

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ABC294640   Start Trial Sphingosine pathway modulating compounds for the treatment of cancers Enzo Biochem, Inc. (New York, NY)   Start Trial
ABC294640   Start Trial Sphingosine kinase inhibitors Apogee Biotechnology Corporation (Hershey, PA)   Start Trial
ABC294640   Start Trial Sphingosine kinase inhibitors Apogee Biotechnology Corporation (Hershey, PA)   Start Trial
ABC294640   Start Trial Sphingosine kinase inhibitors Apogee Biotechnology Corporation (Hershey, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ABC294640

Drugname Country Document Number Estimated Expiration Related US Patent
ABC294640 World Intellectual Property Organization (WIPO) 2018237379 2037-06-23   Start Trial
ABC294640 Australia 2006261327 2025-06-17   Start Trial
ABC294640 Brazil PI0611966 2025-06-17   Start Trial
ABC294640 Canada 2612338 2025-06-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
McKinsey
McKesson
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.